This page contains recent news articles, when available, and an overview of Procrit but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Procrit

Aranesp, Epogen and Procrit Blood Clot Risk Confirmed: Study  -  ‎Nov 11, 2009‎
AboutLawsuits.comAccording to new research, the anti-anemia drugs Aranesp, Epogen and Procrit not only increase the risk of blood clots, but they also do not appear to be ...

Doctor convicted on all 28 counts of fraud  -  ‎Nov 17, 2009‎
The Virginian-PilotHe also billed for vials of Procrit when patients brought in their own medicine. "In addition, the evidence showed that he altered records to obstruct and ...

Amgen Is Accused of Illegal Kickbacks  -  ‎Oct 30, 2009‎
New York TimesAmgen competes with Johnson & Johnson, which sells a similar drug called Procrit, that is also manufactured by Amgen under a licensing agreement. ...

Trial Holds Bad News for Cancer Patients, Amgen  -  ‎Nov 2, 2009‎
GoozNew (blog)The bottom line is that Aranesp, and perhaps by extension Procrit/Epogen, which are short-acting versions of the same recombinant protein, ...

Patterns of Use of Erythropoiesis-stimulating Agents in Medicare Population ...  -  ‎Nov 19, 2009‎
Cancer Consultants...[1] Procrit and Aranesp are widely used to prevent and treat anemia in cancer patients. Virtually all randomized studies have shown a decreased need for ...

Johnson & Johnson to axe 8190 global jobs  -  ‎Nov 3, 2009‎
Times OnlineSales of its anti-anemia treatment Procrit have also declined this year. Johnson & Johnson said cost savings would help provide additional resources to ...

ASN: Comorbidities Determine Effects of Raising Hemoglobin  -  ‎Nov 3, 2009‎
MedPage TodayThe primary CHOIR results found that treating anemic patients who were not on dialysis with epoetin-alfa (Epogen, Procrit) to achieve a target hemoglobin of ...

Band-Aid Won't Stop Generic Bleeding at Johnson & Johnson  -  ‎Nov 11, 2009‎
BNETMore worrisome, the workhorse drug Procrit (epoetin alfa) is starting to look like its got a stone embedded in one hoof: this biologic, an injectable ...

Amgen's troubles keep compounding; Aranesp studies reveal greater risks  -  ‎Nov 11, 2009‎
Daily Finance (blog)Amgen's drug Epogen and Johnson & Johnson's (JNJ) Procrit belong to the same family of drugs, called erythropoiesis-stimulating agents (ESAs). ...

Nearly Half of Dialysis Clinics Do Not Specify Hemoglobin Range  -  ‎Nov 10, 2009‎
Renal Business Today...patients have anemia, which can be treated with erythropoietin-stimulating agents—such as Amgen's Epogen and Aranesp or Johnson & Johnson's Procrit. ...

Will New Anemia Drug Top Current Treatments?  -  ‎Nov 4, 2009‎
Atlanta Journal ConstitutionBut he said it is too early to tell whether Hematide can replace the erythropoietin drugs Procrit and Aranesp, which are associated with heightened risk of ...

Featured Clinical Trial: Combination Therapy for Patients with Myelodysplastic ...  -  ‎Nov 17, 2009‎
National Cancer Institute - NCI Cancer Bulletin...risk of progression to leukemia will be treated with lenalidomide, and some will also receive a form of erythropoietin called epoetin alfa (Procrit). ...

US Oncology Reports Third Quarter Operating Results  -  ‎Nov 5, 2009‎
ReutersUnited States Food and Drug Administration ("FDA") published a final new label for Erythropoiesis-Stimulating Agents ("ESAs") drugs Aranesp and Procrit. ...

Foundry Closes Three  -  ‎Nov 16, 2009‎
Publishers WeeklySharp, an investigative journalist, explores the Procrit case, in which two Johnson & Johnson sales reps claimed the company offered kickbacks to doctors ...

Amgen suit unveils industry 'overfilling' practices  -  ‎Nov 10, 2009‎
Trading Markets (press release)It went on to state that, around the time it launched Aranesp, Amgen started lowering the overfill amounts in Epogen, its earlier anemia drug, and Procrit, ...

Federal appeals court to consider suit challenging Michigan's affirmative ...  -  ‎Nov 17, 2009‎
Gaea TimesTwo former salespeople for the health care giant allege J&J illegally marketed its blockbuster anemia drug Procrit. July 2nd, 2009 Obama downplays ...

Estudio: Riesgo de apoplejía por fármaco contra la anemia  -  ‎Oct 31, 2009‎
Houston ChronicleEpogen y Procrit, al aumentar los temores de que puedan empeorar las posibilidades de supervivencia en pacientes con ciertos tipos de cáncer, ...

دراسة تحذر مريض السرطان من تناول أدوية ?قر الدم  -  ‎Nov 11, 2009‎
بابوعادة ما توص? عقاقير مثل Procrit وAranesp لمكا?حة ?قر الدم المرتبط بأمراض الكلى المزمنة والعلاج الكيمياوي . وتؤكد الدراسة - التي ستنشر ?ي دورية (المعهد ...

양대 빈혈약 “색전? 유발?  -  ‎Nov 10, 2009‎
헬스코리아뉴스...주민우 기? [헬스코리아뉴스] 암젠사? 빈혈약 '아?네스프(Aranesp)'와 존슨앤존슨사? '프로?리트(procrit)'가 치명?? 혈전? 유발하는 정맥혈전 색전?? 유발 ...

조혈 ?극제 빈혈약, 혈전 ?성 위험 2배 높여  -  ‎Nov 10, 2009‎
데일리팜...대??? 조혈?극제로는 암젠? '아?네스프(Aranesp)'와 '???(Epogen)', J&J? '프로?리트(Procrit)'가 있다. 지난 2006년 J&J? ?한 연구결과 조혈?극제를 ...

Dialysecentra VS negeren waarschuwingen EPO-gebruik  -  ‎Nov 11, 2009‎ praktijk niet in overeenstemming zou zijn met de waarschuwingen voor de toepassing van Epogen en Aranesp van Amgen en Procrit van Johnson & Johnson. ...

סכנה לקרישי ד? משימוש בתרופות ל?נמיה  -  ‎Nov 11, 2009‎
News1 מחלקה ראשונה...מכירות התרופות, כולל ?רנספ (Aranesp) ו?פוגן (Epogen) של ?מגן, ופרוקריט (Procrit) של ג'ונסון ג'ונסון ירדו בצורה חדה מ?ז שמחקר שנעשה על-ידי ג'ונסון ג'ונסון ...

Μελέτη επιβεβαιώνει τον κίνδυνο θ?όμβωσης από τις ε?υθ?οποιητίνες  -  ‎Nov 15, 2009‎
Healthviewκαι οδήγησαν σε κατακό?υφη πτώση των πωλήσεων των εν λόγω φα?μάκων, όπως των Aranesp και Epogen της Amgen και του Procrit της Johnson & Johnson. ...

Anemia drug safe when used properly  -  07 Aug 2009
SunJournal.comThe specialist says my kidneys are not putting out enough hormone to correct my anemia, and he wants to give me Procrit if my blood pressure can be

Johnson & Johnson Q2 2009 Earnings Call Transcript  -  ‎Jul 14, 2009‎
Seeking AlphaPROCRIT/EXPREX declined operationally by 6% during the quarter as compared to the same quarter last year, with PROCRIT down 4.6% and EXPREX down 7.6%

US Oncology Reports Second Quarter Operating Results  -  ‎Aug 6, 2009‎
PR Newswire (press release)United States Food and Drug Administration ("FDA") published a final new label for Erythropoiesis-Stimulating Agents ("ESAs") drugs Aranesp and Procrit.

2009's Best Biotech Stocks  -  ‎Aug 5, 2009‎
Wealth DailyThey sell everything from Aveeno. . . to liquid stitches. . . to the cancer drug Procrit. And last month, JNJ paid $893.7 million for Cougar Biotechnology,

Health Information  -  ‎Aug 5, 2009‎
Reno Gazette JournalHowever, recently FDA has seen two highly publicized examples of counterfeit Lipitor and Procrit within the US distribution system.

J&J pharma sales hit by generics but Remicade revenue soars  -  ‎Jul 15, 2009‎
Pharma TimesSales of J&J's anaemia therapy Procrit/Eprex (epoetin alfa) fell 11.5% to $577 million, hurt by continued concerns over cardiovascular safety for the entire

Nephrologists Indicate High Interest in AMAG Pharmaceuticals ...  -  ‎Aug 4, 2009‎
PR Newswire (press release)This adds importance to Nephrologists' perception that Centocor-Ortho Biotech's Procrit has a competitive advantage over Amgen's Aranesp on "minimal hassles

Medicare Dialysis Rules Affecting Amgen Could Come Soon  -  ‎Jul 16, 2009‎ for kidney-failure patients on dialysis because Amgen licensed other uses of the drug to Johnson & Johnson ( JNJ), which sells it as Procrit.

Callison: Living with cancer  -  ‎Jul 22, 2009‎
Sioux Falls Argus LeaderRich also became an expert on Procrit, a medication that increases the production of red blood cells, thereby reducing fatigue among people undergoing

Even if Follow-on Biologics Legislation Passes, PBMs May Face ...  -  ‎Jul 20, 2009‎
Atlantic Information Services, Inc....a managing principal of Boston-based consulting firm Analysis Group, Inc. Among those drugs are the anemia drugs Epogen and Procrit.

J&J 2분기 제약매출 13.3% 하?  -  ‎Jul 14, 2009‎
디지틀보사...프로?리트'(Procrit, epoetin alfa)? 안전성 우려로 매출? 11.5% ?소한 5억7700만달러? 머물렀다. 반면, '레미케?드'(Remicade, infliximab)? 매출? 24.4%

Johnson & Johnson reduce sus ganancias  -  ‎Jul 14, 2009‎
CNNExpansión.comLa caída en las ventas de Procrit y Eprex, medicamentos para la anemia acechados por dudas sobre su seguridad, no fueron tan malas como se temía, afirmó.

強生第二季盈利下? ?申全年?期  -  ‎Jul 14, 2009‎
新浪網...抗貧血藥Procrit的銷售?下?了12%,至11億美元。 券商RBC Capital的分?師們周一表示,?計強生第二季藥物銷售?將下?18%,至52億美元,部分原因是由於其最近失去

强生第二季盈利下? ?申全年预期  -  ‎Jul 14, 2009‎
解放网...抗贫血?Procrit的销售?下?了12%,至11亿美元。 券商RBC Capital的分?师们周一表示,预计强生第二季?物销售?将下?18%,至52亿美元,部分原因是由于其最近失去

强生第二季获利超预期  -  ‎Jul 14, 2009‎
证券之星...出于对安全性的担忧,两?治疗贫血的?物Procrit和Eprex销售下?,但?幅??担心的那样差. 消费者产?的全?销售?少4.5%,至38.5亿美元,而医疗设备和诊断仪器的销售也

Background information on Procrit [When available]

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:
  • Stop or slow the growth of cancer cells.
  • Make it easier for your immune system to destroy, or get rid of, cancer cells.
  • Keep cancer from spreading to other parts of your body.
More from the National Cancer Institute

Search the web for more resources on Procrit

Health Home | Conditions | Cancer | Medications | Surgery | Vaccines

The Cancer News Network


Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on lead to other sites. does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is responsible for dead or misdirected links.

We will do our best to accommodate your request.